Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKOY58
|
|||
| Drug Name |
AZD3366
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Cardiovascular disease [ICD-11: BA00-BE2Z] | Phase 1 | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04588727) A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3366 in Healthy Men and Women of Non-Childbearing Potential Following: Part A: Single Ascending Dose Administration (Including Populations of Japanese and Chinese Subjects) Part B: Single Dose Administration of AZD3366 at One Dose Level or Placebo With Concomitant Repeated Dosing of Ticagrelor and Acetylsalicylic Acid. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of AstraZeneca | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.